Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Awareness Efforts Aim to Drive Earlier Esophageal Cancer Detection Amid Rising Incidence Rates

April 25th 2025

Nataliya Uboha, MD, PhD, highlights the importance of standard endoscopic procedures for the early detection of esophageal cancer.

Rina-S Displays Early Efficacy in Advanced Ovarian Cancer

April 25th 2025

Elizabeth K. Lee, MD, discusses data from the phase 1/2 RAINFOL-01 study of Rina-S in advanced ovarian cancer.

Dr McNall-Knapp on the Efficacy of MEK Inhibition in NF1-Associated PNs

April 24th 2025

Rene Y. McNall-Knapp, MD, discusses the current treatment paradigm for pediatric and adult patients with NF1-associated PNs.

Dr Oberstein on Clinical Applications for Oncodetect in MRD Detection in Solid Tumors

April 24th 2025

Paul E. Oberstein, MD, discusses the clinical applications of the Oncodetect test for molecular residual disease detection in patients with solid tumors.

Dr Ali on the Potential SOC Role of Palbociclib Plus Anti-HER2 and Endocrine Therapy in HER2+ Breast Cancer

April 24th 2025

Azka Ali, MD, discusses the use of palbociclib to overcome resistance to anti-HER2 and endocrine therapies in HER2-positive breast cancer.

Japanese Approval Is Sought for T-DXd in HER2+ Advanced Solid Tumors

April 24th 2025

Japan’s Ministry of Health has received a supplemental new drug application for T-DXd for HER2-positive advanced or recurrent solid tumors.

Optune Lua Granted CE Mark Approval in EU for Metastatic NSCLC

April 24th 2025

A CE Mark has been granted to Optune Lua concurrent with immune checkpoint inhibitors or docetaxel for patients with metastatic non–small cell lung cancer.

Dr Randall on the Surgical Management of Low-Grade Chondrosarcoma

April 23rd 2025

R. Lor Randall, MD, FACS, discusses whether patients with low-grade chondosarcomas should undergo intralesional curettage or en bloc resection.

Dr Ahmed on the Safety Profile of NKTR-255 in Relapsed/Refractory LBCL

April 23rd 2025

Sairah Ahmed, MD, discusses safety data with NKTR-255 in patients with relapsed/refractory large B-cell lymphoma.

Cultural Competency and Respect Are Crucial for Addressing Disparities in Cancer Care

April 23rd 2025

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.

Updated ASCO Living Guidelines Highlight Need for Timely, Patient-Friendly Communication in Stage IV NSCLC

April 23rd 2025

Fawzi F Abu Rous, MD, discusses updates to the ASCO Living Guidelines for the management of stage IV non–small cell lung cancer with driver alterations.

Dr Harrison on Factors Influencing Patient Prognosis and Treatment Selection in Myelofibrosis

April 22nd 2025

Claire Harrison, MD, FRCP, FRCPath, discusses factors informing treatment selection for patients with myelofibrosis.

Dr Farid on Current and Future Investigations of MDC-CAR-BCMA001 in Myeloma and AL Amyloidosis

April 22nd 2025

Kiavasch Mohammad Nejad Farid, MD, discusses 2 planned investigations of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and AL amyloidosis.

Nadofaragene Firadenovec Yields High 3-Month CR Rates in High-Risk BCG-Unresponsive NMIBC With CIS

April 22nd 2025

Nadofaragene firadenovec was safe and produced high CR rates at 3 months in Japanese patients with high-risk BCG-unresponsive NMIBC and CIS.

Female Leadership and Representation in Oncology Is an Immense ‘Honor and Responsibility’

April 22nd 2025

Reshma Lillaney Mahtani, DO, highlights her experience as a leader in oncology and emphasizes the need to further uplift other women in the field.

Dr Rampal on the Benefits and Limitations of JAK Inhibitors in Myelofibrosis

April 21st 2025

Raajit Rampal, MD, discusses treatment decision-making factors, such as JAK inhibitor efficacy and signs of treatment failure, for myelofibrosis.

Dr Flora on the Implications of Emerging AI Models for Oncology Care

April 21st 2025

Douglas B. Flora, MD, LSSBB, discusses the potential utility of GPT models for improving clinical trial screening and workflows in oncology.

Dr Ip on Reasons for Studying Real-World CAR T-Cell Therapy Outcomes in LBCL

April 21st 2025

Andrew Ip, MD, discusses the need for real-world studies investigating the efficacy and safety of CAR T-cell therapy in patients with LBCL.

Dr Bowman on Risk Factors for Kidney Cancer Development

April 21st 2025

I. Alex Bowman, MD, discusses recommended strategies for kidney cancer risk reduction.

Early ESR1 Mutation Detection via ctDNA Monitoring Could Enhance Treatment Adaptation in HR+ Breast Cancer

April 21st 2025

Sara M. Tolaney, MD, MPH, discusses the value of incorporating ctDNA monitoring of ESR1 mutations into routine management for HR-positive breast cancer.